Cruz Heidi S Santa, Verdial Francys C, Shanno Julia N, Webster Alexandra J, Jimenez Rachel B, Oseni Tawakalitu O, Ozmen Tolga, Kwait Rebecca M, Gadd Michele A, Specht Michelle C, Smith Barbara L
Division of GI and Oncologic Surgery, Breast Surgery Section, Massachusetts General Hospital, Boston, MA.
Division of GI and Oncologic Surgery, Breast Surgery Section, Massachusetts General Hospital, Boston, MA.
Clin Breast Cancer. 2025 Jan;25(1):e63-e70. doi: 10.1016/j.clbc.2024.07.010. Epub 2024 Aug 3.
Axillary recurrence following lumpectomy with a negative sentinel lymph node biopsy (SLNB) is rare, possibly due to routine use of whole breast radiation. In this study, we characterized the rate of any axillary recurrence among mastectomy patients with a negative SLNB and no adjuvant radiation therapy.
We identified women who underwent mastectomy with SLNB for early-stage breast cancer (1999-2005) and included patients with pathologically negative nodes and no axillary dissection or adjuvant radiation. The primary outcome was ipsilateral axillary recurrence.
A total of 234 women, median age 50 years, underwent 242 mastectomies. Histology showed 112 (46%) invasive cancers, 16 (7%) ductal carcinoma in-situ (DCIS) with microinvasion, and 114 (47%) pure DCIS. Cancers were predominantly estrogen receptor positive (59%) and moderate (41%) or high grade (32%). A mean of 2 final sentinel nodes were excised (range 1-6) and 21 patients (9%) had isolated tumor cells on SLNB pathology. At 16 years median follow up (range 1-22 years), 3 patients (1.2%) developed an isolated axillary failure, and 1 had concurrent axillary and chest wall recurrences (total axillary recurrence rate 1.7%). Three of four axillary recurrences occurred in patients with moderate or high-grade estrogen receptor-positive DCIS without invasion on mastectomy histology. Median time to axillary recurrence was 70.5 months (range 29-132 months).
Axillary recurrence is rare after a negative SLNB, even in the absence of adjuvant radiation. This supports the safety of forgoing additional surgery or radiation to the axilla in the early-stage breast cancer and a negative SLNB.
保乳手术联合前哨淋巴结活检(SLNB)结果为阴性后出现腋窝复发的情况较为罕见,这可能归因于全乳放疗的常规应用。在本研究中,我们对接受乳房切除术且SLNB结果为阴性且未接受辅助放疗的患者中腋窝复发的发生率进行了特征分析。
我们确定了1999年至2005年期间因早期乳腺癌接受乳房切除术联合SLNB的女性患者,并纳入了病理检查淋巴结阴性且未进行腋窝清扫或辅助放疗的患者。主要结局为同侧腋窝复发。
共有234名女性患者,中位年龄50岁,接受了242次乳房切除术。组织学检查显示,有112例(46%)浸润性癌,16例(7%)伴有微浸润的导管原位癌(DCIS),以及114例(47%)纯DCIS。癌症主要为雌激素受体阳性(59%),中度(41%)或高级别(32%)。平均切除2个最终前哨淋巴结(范围为1至6个),21例患者(9%)在SLNB病理检查中发现孤立肿瘤细胞。在中位随访16年(范围为1至22年)时,3例患者(1.2%)出现孤立性腋窝复发,1例患者同时出现腋窝和胸壁复发(总腋窝复发率为1.7%)。4例腋窝复发中有3例发生在乳房切除组织学检查显示为中度或高级别雌激素受体阳性DCIS且无浸润的患者中。腋窝复发的中位时间为70.5个月(范围为29至132个月)。
SLNB结果为阴性后腋窝复发罕见,即使未进行辅助放疗也是如此。这支持了对于早期乳腺癌且SLNB结果为阴性的患者,无需对腋窝进行额外手术或放疗的安全性。